Phaseline

Targets › CCKAR

CCKAR (Cholecystokinin receptor type A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2028.

Receptor for cholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. (UniProt, P32238)

Open in Phaseline: the race on CCKAR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterGastrin-17 (GAST-17)
Gastrin receptor agonist; gut hormone to promote islet cell growth and survival
CCKARPhase 1Diabetes Mellitus, Type 1Aug 2028

Conditions

Diabetes Mellitus, Type 1 (1)

Modalities

mixed (1)

Companies

City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.